Please login to the form below

Not currently logged in
Email:
Password:

Sanofi to pay $750m for vaccines biotech Protein Sciences

Adds US firm's recombinant-based influenza vaccine to its portfolio

Sanofi-Pasteur building

Sanofi is to acquire Protein Sciences in a deal that could be worth up to $750m for the Connecticut, US-based biotech company.

In doing so Sanofi can add Protein Sciences’ flu vaccine Flublok, which was licensed in the US in 2013 and is currently the only recombinant protein-based influenza vaccine approved by the FDA.

David Loew, Sanofi executive vice president and head of its vaccines division Sanofi Pasteur, said: "The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine."

Sanofi’s vaccines portfolio already includes the four-in-one influenza vaccine Fluzone Quadrivalent, which the FDA approved in June 2013. But the addition of Flublok brings a vaccine that can be used by those with egg allergies and has shorter production timelines than tradition vaccines.

Manon M.J. Cox, Protein Sciences’ president and CEO, added: "Protein Sciences was actively looking for an opportunity to grow its business, particularly in the US. As part of Sanofi Pasteur, we expect our Flublok influenza vaccine to benefit from Sanofi Pasteur's expertise in the field of influenza vaccines."

The acquisition has unanimous approval by Protein Sciences’ board of directors and a majority of the firm’s shareholders, and is expected to close in the third quarter of 2017.

At the start of this year Sanofi finalised the split of its long-standing vaccines alliance with Merck & Co, a move that came in the wake of poor sales growth at their Sanofi Pasteur MSD joint venture.

Its deal with Protein Sciences follows unsuccessful bids in the last year for Actellion, which it lost out to J&J, and Medivation after it was acquired by Pfizer.

Article by
Dominic Tyer

11th July 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics